immunotherapy

October 2, 2017October 2, 2017

Incysus Seeks FDA Approval to Start Blood Cancer Trials for Its γδ T-Cell Immunotherapy

News

Incysus has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start clinical development of its expanded and activated allogeneic gamma-delta (γδ) T-cell ... Read more

August 31, 2017September 1, 2017

FDA Approves First-Ever CAR T-Cell Therapy, Kymriah, for Young B-Cell ALL Patients

News

In what is described as a historical decision, the U.S. Food and Drug Administration (FDA) has approved the first gene therapy-based cancer treatment in the United States. The FDA approved Novartis’ ... Read more

August 14, 2017August 14, 2017

CAR T-Cell Therapy Shown to Eliminate Tumors in Some Chronic Lymphocytic Leukemia Patients During Trial

News

CAR T-cell immunotherapy was seen to eradicate or shrink tumors in 70% of patients with chronic lymphocytic leukemia (CLL) who had exhausted other treatment options, according to a clinical trial ... Read more

June 15, 2017

37% of Those Who Received CTL019 in Phase 2 Clinical Trial Had Their Lymphoma Disappear

News

Thirty-seven percent of patients with a difficult-to-treat lymphoma had their cancer disappear after receiving Novartis’ CTL019 (tisagenlecleucel), according to an interim analysis of Phase 2 clinical trial results. Other patients achieved ... Read more

March 7, 2017March 7, 2017

UNC Lineberger Cancer Center Launches Lymphoma Trials with CAR T-cells

News

The University of North Carolina Lineberger Comprehensive Cancer Center has launched two clinical trials exploring CAR T-cells in patients with lymphoma, making it easier for patients in the Southeast to participate in ... Read more

February 16, 2017

Lymphoma Patients Respond to Pembrolizumab After Other Therapies Fail, Small Study Indicates

News

Patients with NK-cell or T-cell lymphomas whose previous treatments failed showed remarkably good responses to the immunotherapy Keytruda (pembrolizumab) in a small trial. The study, “PD1 blockade with pembrolizumab is ... Read more

November 28, 2016November 28, 2016

Leukemia & Lymphoma Society to Invest $40M in New Research into Blood Cancers

News

The Leukemia & Lymphoma Society (LLS) announced that it will invest $40.3 million in new efforts to advance promising blood cancer research at leading scientific and medical centers worldwide. The investment adds 75 new research grants ... Read more

October 26, 2016

Immunotherapy Combo Shows Long-lasting Responses in Large Mouse Tumors

News

Combining immunotherapies to activate both arms of the immune system — the innate and adaptive — can effectively eliminate lymphoma in mice and generate immune cells that recognize new tumor ... Read more

September 22, 2016

AACR’s 2016 Cancer Progress Report: Immunotherapy and Research Leading to Notable Advances

News

The number of cancer patients benefiting from immunotherapies and being treated successfully is increasing markedly, according to the Sixth Annual Cancer Progress Report recently released by the American Association for Cancer Research ... Read more

June 15, 2016

Patient Testimony: Life After Immunotherapy for Lymphoma

The most common courses of treatment for Hodgkin lymphoma are chemotherapy, radiation therapy, or a combination of the two. However, immunotherapy is also an option, and in the case of ... Read more